Published in Carcinogenesis on January 06, 2012
WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 38.72
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell (1993) 33.20
Intrinsic tumour suppression. Nature (2004) 8.73
Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol (2006) 6.06
p19ARF links the tumour suppressor p53 to Ras. Nature (1998) 4.89
Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood (2002) 3.89
Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta (2002) 3.77
Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res (1996) 3.50
High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res (1996) 3.18
T-cell development and the CD4-CD8 lineage decision. Nat Rev Immunol (2002) 3.09
Deletion of p16 and p15 genes in brain tumors. Cancer Res (1994) 3.03
Development and selection of T cells: facts and puzzles. Adv Immunol (1995) 2.70
Selective requirement for MAP kinase activation in thymocyte differentiation. Nature (1995) 2.53
Productive T-cell receptor beta-chain gene rearrangement: coincident regulation of cell cycle and clonality during development in vivo. Genes Dev (1996) 2.47
Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res (2001) 2.37
p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res (2001) 2.34
Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1. Science (1997) 2.33
Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis. EMBO J (2000) 2.21
Cooperating oncogenes converge to regulate cyclin/cdk complexes. Genes Dev (1997) 1.88
Many faces of Ras activation. Biochim Biophys Acta (2008) 1.74
Pleiotropic changes controlled by the pre-T-cell receptor. Curr Opin Immunol (1999) 1.71
p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood (1999) 1.71
Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia (1998) 1.68
RAS pathways to cell cycle control and cell transformation. Front Biosci (1998) 1.60
Hypermethylation of GpG islands in the promoter region of p15(INK4b) in acute promyelocytic leukemia represses p15(INK4b) expression and correlates with poor prognosis. Leukemia (2003) 1.49
Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer (1997) 1.42
Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p15(INK4b). Mol Cell Biol (2000) 1.41
Tumorigenic activity of p21Waf1/Cip1 in thymic lymphoma. Oncogene (2006) 1.32
Multiple p21ras effector pathways regulate nuclear factor of activated T cells. EMBO J (1996) 1.24
Isolation of high molecular weight DNA for reliable genotyping of transgenic mice. Biotechniques (1997) 1.21
Hypermethylation of the Ink4b locus in murine myeloid leukemia and increased susceptibility to leukemia in p15(Ink4b)-deficient mice. Oncogene (2003) 1.18
DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia. Cancer Res (2007) 1.15
Isolation, characterization, and chromosome assignment of mouse N-ras gene from carcinogen-induced thymic lymphoma. Science (1984) 1.15
Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res (1999) 1.15
Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas. Blood (1999) 1.13
rsc: a novel oncogene with structural and functional homology with the gene family of exchange factors for Ral. Oncogene (1997) 1.09
Inactivation of the cyclin-dependent kinase inhibitor p15INK4b by deletion and de novo methylation with independence of p16INK4a alterations in murine primary T-cell lymphomas. Oncogene (1997) 1.07
Hypermethylation of p16 and p15 genes and RB protein expression in acute leukemia. Leuk Res (2000) 1.07
CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma. Mod Pathol (2010) 1.06
Activated N-ras oncogene and N-ras proto-oncogene act through the same pathway for in vivo tumorigenesis. Oncogene (1996) 1.05
Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood (1995) 1.02
CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer (2003) 0.95
Distinct Ras effector pathways are involved in Fc epsilon R1 regulation of the transcriptional activity of Elk-1 and NFAT in mast cells. J Exp Med (1997) 0.95
Hypermethylation of a 5' CpG island of p16 is a frequent event in non-Hodgkin's lymphoma. Leukemia (1997) 0.95
Life and death in the thymus--cell death signaling during T cell development. Curr Opin Cell Biol (2010) 0.93
Rac-1 regulates nuclear factor of activated T cells (NFAT) C1 nuclear translocation in response to Fcepsilon receptor type 1 stimulation of mast cells. J Exp Med (1998) 0.91
Differential expression of cell cycle regulators in phenotypic variants of transgenically induced bladder tumors: implications for tumor behavior. Cancer Res (2005) 0.90
p16INK4A and p15INK4B gene deletions in primary leukemias. Blood (1995) 0.90
Hypermethylation of the cell cycle inhibitor p15INK4b 3'-untranslated region interferes with its transcriptional regulation in primary lymphomas. Oncogene (1999) 0.87
Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin's and CD30-Positive non-Hodgkin's lymphomas. Am J Pathol (2002) 0.86
rgr oncogene: activation by elimination of translational controls and mislocalization. Cancer Res (2003) 0.84
The Rgr oncogene (homologous to RalGDS) induces transformation and gene expression by activating Ras, Ral and Rho mediated pathways. Oncogene (2000) 0.82
Hypermethylation of p15/ink4b/MTS2 gene is differentially implicated among non-Hodgkin's lymphomas. Leukemia (1998) 0.80
Human rgr: transforming activity and alteration in T-cell malignancies. Oncogene (2002) 0.79
The human Rgr oncogene is overexpressed in T-cell malignancies and induces transformation by acting as a GEF for Ras and Ral. Oncogene (2011) 0.78
p15ink4B and p16ink4 gene inactivation in acute lymphocytic leukemia. Blood (1995) 0.78
The Rgr oncogene induces tumorigenesis in transgenic mice. Cancer Res (2004) 0.77
A simple DNA extraction method suitable for PCR detection of genetically modified maize. J Sci Food Agric (2007) 0.76
Phospholipase Cgamma activates Ras on the Golgi apparatus by means of RasGRP1. Nature (2003) 3.66
Uroplakins in urothelial biology, function, and disease. Kidney Int (2009) 1.79
Ras activation in Jurkat T cells following low-grade stimulation of the T-cell receptor is specific to N-Ras and occurs only on the Golgi apparatus. Mol Cell Biol (2004) 1.66
LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Res (2009) 1.34
Systemic tumor targeting and killing by Sindbis viral vectors. Nat Biotechnol (2003) 1.31
Differences on the inhibitory specificities of H-Ras, K-Ras, and N-Ras (N17) dominant negative mutants are related to their membrane microlocalization. J Biol Chem (2002) 1.31
The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene. Cancer Res (2002) 1.23
Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. Cancer Res (2002) 1.16
Regulation of HMGA1 expression by microRNA-296 affects prostate cancer growth and invasion. Clin Cancer Res (2010) 1.11
Using sindbis viral vectors for specific detection and suppression of advanced ovarian cancer in animal models. Cancer Res (2004) 1.09
Mice deficient for N-ras: impaired antiviral immune response and T-cell function. Cancer Res (2003) 1.07
Origin of the tetraspanin uroplakins and their co-evolution with associated proteins: implications for uroplakin structure and function. Mol Phylogenet Evol (2006) 1.02
Inhibition of Ras oncogenic activity by Ras protooncogenes. Int J Cancer (2005) 1.01
p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis. Oncogene (2004) 1.01
Differential expression of cell cycle regulators in phenotypic variants of transgenically induced bladder tumors: implications for tumor behavior. Cancer Res (2005) 0.90
Lung-specific expression of dominant-negative mutant p53 in transgenic mice increases spontaneous and benzo(a)pyrene-induced lung cancer. Am J Respir Cell Mol Biol (2002) 0.88
Complex effects of Ras proto-oncogenes in tumorigenesis. Carcinogenesis (2003) 0.85
rgr oncogene: activation by elimination of translational controls and mislocalization. Cancer Res (2003) 0.84
NF1 modulates the effects of Ras oncogenes: evidence of other NF1 function besides its GAP activity. J Cell Physiol (2003) 0.84
The differential palmitoylation states of N-Ras and H-Ras determine their distinct Golgi subcompartment localizations. J Cell Physiol (2015) 0.82
Mouse p10, an alternative spliced form of p15INK4b, inhibits cell cycle progression and malignant transformation. Cancer Res (2005) 0.80
Human rgr: transforming activity and alteration in T-cell malignancies. Oncogene (2002) 0.79
Wild type N-ras displays anti-malignant properties, in part by downregulating decorin. J Cell Physiol (2012) 0.77
The Rgr oncogene induces tumorigenesis in transgenic mice. Cancer Res (2004) 0.77
Biochemical and biological analyses of Rgr RalGEF oncogene. Methods Enzymol (2006) 0.76
In TCR-stimulated T-cells, N-ras regulates specific genes and signal transduction pathways. PLoS One (2013) 0.76